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Abstract. Background/Aim: Dual-specificity protein
phosphatase 4 (DUSP4) negatively regulates MAPK signaling
and is involved in various cellular processes. We herein
evaluated the relationship between DUSP4 expression and
clinicopathological characteristics in a large series of gastric
cancer samples. Materials and Methods: DUSP4 expression
was examined by immunohistochemistry in 508 gastric cancer
samples. Cases were classified according to the TCGA
molecular classification and HER2 amplification. Kaplan-
Meier plots were used to predict the relationship between
mRNA expression of DUSP4 and survival. Results: Low
expression of DUSP4 was significantly correlated with larger
tumor size, higher pT category, positive nodal status, higher
stage, lymphovascular invasion, perineural invasion, worse
overall survival, and worse recurrence-free survival. No
correlation was observed between DUSP4 expression and
molecular characteristics. Bioinformatics analysis showed that
low mRNA expression was associated with a poor prognosis.
Conclusion: Low expression of DUSP4 is associated with
aggressive phenotypes of gastric cancer and a poor prognosis. 
Gastric cancer is a common epithelial malignant neoplasm
of the digestive system. According to the GLOBOCAN 2018
database, gastric cancer shows the fifth highest incidence and
the third highest mortality rate worldwide (1). It is the most
common cancer in East Asia, including Korea. Although the
age-standardized rate of incidence and death is declining, it
still has a high mortality rate (2). Therefore, it is important
to investigate novel treatment and prognostic biomarkers for
gastric cancer.
Surgical resection is the only method for curative
treatment of gastric cancer, but the prognosis is poor for
advanced or metastatic gastric cancer. Therefore, adjuvant
chemotherapy has been performed to improve survival, and
recent advances in molecular biology have led to discovery
of various targeted therapies. For example, the use of
trastuzumab, an anti-human epidermal growth factor
receptor-2 (HER2) drug, was approved with cytotoxic drugs
for the treatment of metastatic HER2-overexpressing gastric
cancer. Additionally, clinical trials for other molecular targets
(EGFR, CLDN18.2, VEGFR) are ongoing (3).
Dual-specificity protein phosphatase 4 (DUSP4), also
known as mitogen-activated protein kinase phosphatase
(MKP)-2, negatively regulates mitogen-activated protein
kinase (MAPK) signaling and is involved in various cellular
processes such as cell proliferation and immune response (4).
There have been many studies on the role of DUSP4 in
cancer. In vitro studies of EGFR-mutated lung cancer (5),
papillary thyroid carcinoma (6, 7), and pancreatic cancer (8)
revealed increased DUSP4 expression. Low expression of
DUSP4 was associated with a poor prognosis in a study of
diffuse large B-cell lymphoma (9), whereas high expression
of DUSP4 was associated with lymph node metastasis and
extrathyroidal extension in a study of papillary thyroid
carcinoma (7). The relationship between DUSP4 expression
and aggressive features showed contradictory results in
studies of colorectal cancer (10, 11). Low DUSP4 expression
was associated with a poor prognosis in a study of triple-
negative breast cancer (12); however, high DUSP4 expression
was associated with a poor prognosis in early T-stage breast
cancer (13). In vitro studies of gastric cancer cell lines
revealed that up-regulated DUSP4 expression was associated
with drug resistance, epithelial-mesenchymal transition,
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migration, and invasion (14, 15). Immunohistochemical
analysis of gastric cancer tissue confirmed that low DUSP4
expression was associated with sex, tumor size, depth of
invasion, and distant metastasis (16). 
In this study, we evaluated the relationship between DUSP4
expression and the clinicopathological characteristics of
gastric cancer using semi-quantitative immunohistochemical
(IHC) staining in a large series of resected gastric cancer
samples. Additionally, the association between DUSP4
expression and specific molecular subtypes was evaluated.
Materials and Methods 
Clinical data and pathological evaluation. Gastric cancer cases
were retrospectively enrolled as patients who underwent surgical
resection between February 2005 and July 2010 at the Hanyang
University Hospital. A total of 520 cases were collected, and 9 cases
were excluded from the study because they had distant metastasis
at the time of diagnosis or neoadjuvant therapy. In addition, two
cases had a positive surgical margin, and one case was excluded
because the patient died immediately after surgery. Consequently,
508 cases were included in this study. To compare the expression
of DUSP4, 27, 54, and 63 samples of the normal gastric mucosa (≥1
cm from the tumor), adenoma, and lymph node metastasis were
additionally obtained, respectively.
Medical records were reviewed to confirm the patient’s clinical
information including age, sex, adjuvant chemotherapy, death, and
recurrence date. A review of hematoxylin and eosin (H&E) slides and
pathologic reports was performed by two pathologists (SSB and SSP).
Tumor location, and size, gross type, histology, lymphovascular
invasion and perineural invasion, and tumor-node-metastasis (TNM)
stage were evaluated. Tumor histology was classified based on the
Lauren classification and 2019 WHO classification, and the TNM
stage was classified according to the 8th edition of the American Joint
Committee on Cancer (AJCC). The clinicopathological characteristics
of gastric cancer patients are summarized in Table I.
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Table I. Clinicopathological characteristics of gastric cancer cases (n=508).
Characteristics Case No. (%) Characteristics Case No. (%) 
Age, median (range, year) 62 (25-90) Lauren classification
Gender Intestinal 212 (41.7%)
Male 352 (69.3%) Diffuse 128 (25.2%)
Female 156 (30.7%) Mixed (including indeterminate) 168 (33.1%)
Tumor size, mean (range, cm) 4.1 (0.3-20.0) Lymphovascular invasion
Location (center of tumor) Present 254 (50.0%)
Cardia 15 (3.0%) Not identified 254 (50.0%)
Fundus 2 (0.4%) Perineural invasion
Body 164 (32.3%) Present 193 (38.0%)
Angle 23 (4.5%) Not identified 315 (62.0%)
Antrum 296 (58.3%) pT category
Pylorus 8 (1.6%) 1a 167 (32.9%)
Gross type (Early gastric cancer) 1b 100 (19.7%)
Type I 14 (5.2%) 2 48 (9.4%)
Type IIa 26 (9.7%) 3 102 (20.1%)
Type IIb 36 (13.5%) 4a 84 (16.5%)
Type IIc 148 (55.4%) 4b 7 (1.4%)
Type III 13 (4.9%) pN category
Mixed 30 (11.2%) 0 299 (58.9%)
Borrmann type (Advanced gastric cancer) 1 55 (10.8%)
Borrmann type 1 5 (2.1%) 2 59 (11.6%)
Borrmann type 2 52 (21.6%) 3a 46 (9.1%)
Borrmann type 3 155 (64.3%) 3b 49 (9.6%)
Borrmann type 4 29 (12.0%) Stage (AJCC 8th edition) 
Histologic type (by WHO classification, 2019) IA 240 (47.2%)
Tubular adenocarcinoma, well differentiated 74 (14.6%) IB 41 (8.1%)
Tubular adenocarcinoma, moderately differentiated 123 (24.2%) IIA 51 (10.0%)
Tubular adenocarcinoma, poorly differentiated 121 (23.8%) IIB 33 (6.5%)
Papillary adenocarcinoma 2 (0.4%) IIIA 50 (9.8%)
Mucinous adenocarcinoma 14 (2.8%) IIIB 44 (8.7%)
Poorly cohesive carcinoma (including signet ring IIIC 49 (9.6%)
cell carcinoma) 100 (19.7%) Treatment
Other histologic subtypes* 20 (3.9%) Surgery+adjuvant chemotherapy 233 (45.9%)
Mixed adenocarcinoma 54 (10.6%) Surgery 275 (54.1%)
*Other histological subtypes, adenosquamous carcinoma, squamous cell carcinoma, carcinoma with lymphoid stroma, hepatoid adenocarcinoma,
micropapillary adenocarcinoma.
Tissue microarray construction and immunohistochemistry. Tissue
microarray systems (Tissue Microarray Set, Labro, Seoul, Republic
of Korea) and formalin-fixed paraffin-embedded (FFPE) tissue were
used for tissue microarray (TMA) construction. The blocks of
gastrectomy or endoscopic submucosal dissection (ESD) specimens
were used for normal gastric mucosa, tubular adenoma, and gastric
cancer tissue. For LN tissue, the block with the largest metastatic
tumor in the LN dissection specimen was used. After determining
the representative area on the H&E slides by light microscopy,
tissue was collected through a 3.0 mm punch.
Immunohistochemistry was performed to evaluate the expression
of DUSP4. Deparaffinization and rehydration were performed on 4
μm sections by immersing the sections in xylene and graded series
of ethanol. Heat-induced epitope retrieval (100˚C for 20 min in
sodium citrate buffer) and blocking of endogenous peroxidase using
the peroxidase-blocking solution (S2023, Dako, Glostrup, Denmark)
for 15 min were performed. Sections were incubated at 4˚C
overnight with the dilated DUSP4 antibody (1:200, Rabbit DUSP4
polyclonal antibody, ab72593, Abcam, Cambridge, MA, USA).
Labeled polymer and 3,3’-diaminobenzidine tetrahydrochloride
chromogen (K5007, EnVision™ Detection System, Dako, Glostrup,
Denmark) were sequentially used for detection according to the
manufacturer’s instructions.
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Figure 1. Immunohistochemical staining of dual-specificity protein phosphatase 4 (DUSP4) in gastric cancer. (a): Negative , (b): weakly positive
expression, (c): intermediate expression, (d): strong positive expression, ×200.
Table II. DUSP4 expression in various gastric tissues.
Samples Cases DUSP4 expression
Low High p-Value
expression (%) expression (%)
Normal mucosa 27 4 (14.8%) 23 (85.2%) <0.001
Tubular adenoma 54 7 (13.0%) 47 (87.0%)
Gastric cancer 508 233 (45.9%) 275 (54.1%)
LN metastasis 63 34 (54.0%) 29 (46.0%)
DUSP4, Dual-specificity protein phosphatase 4; LN, lymph node.
Interpretation of IHC staining. DUSP4 expression was evaluated by
two pathologists without access to clinical data (SSB and SSP). For
the semi-quantitative assessment, histoscore (H-score) was
calculated based on the intensity and percentage of nuclear DUSP4
expression. The intensity of staining was classified as 0 to 3 (0:
negative, 1: weak, 2: intermediate, 3: strong) and the positive rate
was scored from 0 to 100. Following this, the optimal cutoff value
of DUSP4 expression was determined using the receiver operating
characteristics (ROC) curve, and cases were divided into high or
low expression.
Microsatellite instability and Epstein-Barr virus status. The TCGA
network classified gastric cancer into four molecular subtypes using
comprehensive molecular evaluation: Epstein-Barr virus (EBV),
microsatellite instability (MSI), genomic stability (GS), and
chromosomal instability (CIN) (17). In this study, IHC staining of
mismatch repair proteins was performed to identify the MSI subtype
and EBV-encoded RNA in situ hybridization (EBER-ISH) was
performed to confirm the EBV subtype. IHC staining was performed
on the entire tumor section for MLH1 (G168-728, Cell Marque,
Rocklin, CA, USA), PMS2 (MRQ-28, Cell Marque, CA, USA),
MSH2 (G219-1129, Cell Marque, CA, USA), and MSH6 (PU29,
Leica Biosystems, Nussloch, Germany) and classified as MSI
subtype when one or more results were negative. Cases with diffuse
positivity when stained using the INFORM EBER Probe (Roche,
Basel, Switzerland) on TMA slides were classified as EBV subtype.
HER2 status. IHC and silver DNA in situ hybridization (SISH) tests
were performed on all sections of the TMA to evaluate HER2
amplification. Automatic staining was performed according to the
manufacturer’s instructions with a rabbit monoclonal anti-HER-2
antibody (4B5, Roche) and INFORM HER2 Dual ISH DNA probe
cocktail (Roche). HER2 amplified cases were defined as an IHC
score 3 or a HER2/ chromosome 17 (CEP17) ratio of ≥2.0 (18).
Bioinformatics. Kaplan-Meier plotter (KM plotter, http://kmplot.com/
analysis/) is an online analysis tool that provides the gene expression
data for 1,065 gastric cancer samples (19). It is used to predict the
association between the mRNA expression of biomarker candidates
and the survival of gastric cancer patients. The effect of DUSP4
expression on the prognosis of gastric cancer patients was estimated
using this tool in this study.
Statistical analyses. The Kruskal-Wallis test was performed to
compare DUSP4 expression in normal gastric mucosa, tubular
adenoma, gastric cancer, and lymph node metastasis. Pearson’s chi-
square (χ2) and Fisher’s exact tests were performed to evaluate the
correlation between DUSP4 expression and clinicopathological
factors. The Kaplan-Meier method with log-rank test was performed
to evaluate the influence of DUSP4 expression on overall survival
(OS) and recurrence-free survival (RFS), and univariate and
multivariate Cox regression analyses were performed to identify the
significant prognostic factors. SPSS software version 25.0 (IBM,
Armonk, USA) was used for all statistical analyses, and p-value  
<0.05 was considered statistically significant.
Results
The pattern of DUSP4 expression. Nuclear DUSP4
expression was variable, and representative images are
presented in Figure 1. Cases were divided into high-
expression group (H-score ≥200) and low-expression group
(H-score <200) using the ROC curve. High DUSP4
expression was observed in 23 cases (85.2%) of normal
gastric mucosa, 47 cases (87.0%) of tubular adenoma, 275
cases (54.1%) of gastric cancer, and 29 cases (46.0%) of LN
tissue with gastric cancer metastasis (Table II). DUSP4
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Figure 2. The pattern of Dual-specificity protein phosphatase 4 (DUSP4) expression in normal mucosa, tubular adenoma, gastric cancer, and lymph
node (LN) metastasis (p<0.001, Kruskal-Wallis test).
expression was significantly lower in gastric cancer and
lymph node metastasis than in normal gastric mucosa and
tubular adenoma (p<0.001, Kruskal-Wallis test) (Figure 2).
There was no significant difference in DUSP4 expression
between normal gastric mucosa and tubular adenoma and
between gastric cancer and lymph node metastasis.
The correlation between DUSP4 expression and clinico -
pathological features. The correlation between DUSP4
expression and clinicopathological features was investigated
and is summarized in Table III. Low expression of DUSP4
was significantly correlated with larger tumor size (p<0.001),
presence of lymphovascular invasion (p<0.001), presence of
perineural invasion (p<0.001), higher pT category (p<0.001),
nodal metastasis (p<0.001) and higher stage (p<0.001). No
significant correlation was observed between DUSP4
expression and other features including age, gender, tumor
location, Lauren classification, and histological type.
The correlation between DUSP4 expression and molecular
characteristics. According to the TCGA molecular
classification, 34 cases (6.7%) were classified as EBV subtype
and 40 cases (7.9%) were classified as MSI subtype. The
remaining 434 cases (85.4%) were classified as GS or CIN
subtype. In this study, these two subtypes were not distinguished
and classified as EBV-negative or microsatellite stable (MSS).
There were 24 HER2-amplified cases (4.7%) and these cases
were EBV-negative or MSS. There was no correlation between
DUSP4 expression and molecular characteristics (Table III).
Prognostic significance of various factors including DUSP4
expression. In univariate analyses, various factors
showed a significant association with OS or RFS. Low DUSP4
expression (p=0.028), older age (p<0.001), larger tumor size
(p<0.001), diffuse and mixed type of Lauren classification
(p=0.016), higher pT category (p<0.001), nodal metastasis
(p<0.001), higher TNM stage (p<0.001), lymphovascular
invasion (p<0.001), and perineural invasion (p<0.001) were
associated with short OS. Low DUSP4 expression (p=0.004),
larger tumor size (p<0.001), undifferentiated and other types of
WHO histological classification (p<0.001), diffuse and mixed
type of Lauren classification (p<0.001), higher pT category
(p<0.001), nodal metastasis (p<0.001), higher TNM stage
(p<0.001), lymphovascular invasion (p<0.001), and perineural
invasion (p<0.001) were associated with short RFS. In
multivariate analyses, older age (p<0.001), higher TNM stage
(p<0.001), and perineural invasion (p=0.041) were associated
with short OS, and higher TNM stage (p<0.001) was associated
with short RFS. However, low DUSP4 expression was not
statistically significant (Table IV). Kaplan-Meier survival
analyses revealed that low DUSP4 expression was significantly
associated with short OS and RFS (log-rank test, p=0.027 and
p=0.003, respectively; Figure 3). Similar to our results, the
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Table III. Correlation between DUSP4 expression and clinicopathological
features and molecular characteristics (n=508).
Variables DUSP4 expression p-Value
Low High 
expression (%) expression (%)
Age 0.984
<65 years 140 (45.9%) 165 (54.1%)
≥65 years 93 (45.8%) 110 (54.2%)
Gender 0.284
Female 66 (42.3%) 90 (57.7%)
Male 167 (47.4%) 185 (52.6%)
Tumor size <0.001
<4.0 cm 98 (35.0%) 182 (65.0%)
≥4.0 cm 135 (59.2%) 93 (40.8%)
Location 0.575
Proximal 80 (44.2%) 101 (55.8%)
Distal 153 (46.8%) 174 (53.2%)
Histologic type* 0.252
Differentiated 85 (42.7%) 114 (57.3%)
Undifferentiated 148 (47.9%) 161 (52.1%)
and others
Lauren 0.065
Intestinal 87 (41.0%) 125 (59.0%)
Diffuse and 146 (49.3%) 150 (50.7%)
mixed 
pT category <0.001
pT1 and pT2 108 (34.3%) 207 (65.7%)
pT3 and pT4 125 (64.8%) 68 (35.2%)
Nodal status <0.001
Negative 115 (38.5%) 184 (61.5%)
Positive 118 (56.5%) 91 (43.5%)
Stage <0.001
I 93 (33.1%) 188 (66.9%)
II and III 140 (61.7%) 87 (38.3%)
Lymphovascular <0.001
invasion
Absent 94 (37.0%) 160 (63.0%)
Present 139 (54.7%) 115 (45.3%)
Perineural <0.001
invasion
Absent 110 (34.9%) 205 (65.1%)
Present 123 (63.7%) 70 (36.3%)
EBV status
Negative 213 (44.9%) 261 (55.1%) 0.116
Positive 20 (58.8%) 14 (41.2%)
MSI status
MSS 219 (53.2%) 249 (46.8%) 0.151
MSI 14 (35.0%) 26 (65.0%)
HER2 status
No amplification 220 (45.5%) 264 (54.5%) 0.403
Amplification 13 (54.2%) 11 (45.8%)
*Differentiated: Well-differentiated tubular adenocarcinoma, moderately
differentiated tubular adenocarcinoma, papillary adenocarcinoma;
Undifferentiated: poorly differentiated tubular adenocarcinoma, poorly
cohesive carcinoma; Others: mucinous adenocarcinoma, other histologic
subtypes; Stage, AJCC 8th edition. EBV, Epstein-Barr virus; MSS,
microsatellite stable; MSI, microsatellite instability; HER2, human
epidermal growth factor receptor-2.
analysis using the KM plotter demonstrated that low mRNA
expression of DUSP4 was associated with unfavorable survival
outcomes (log-rank test, p<0.001; Figure 4). 
Discussion
In the present study, immunohistochemical staining for
DUSP4 was performed in normal gastric mucosa, tubular
adenoma, gastric cancer, and LN tissue with gastric cancer
metastasis. Our results demonstrated that the expression of
DUSP4 was significantly lower in gastric cancer and
metastatic tumors than that in normal gastric mucosa and
tubular adenoma. Low expression of DUSP4 was significantly
associated with larger tumor size, higher pT stage, nodal
metastasis, lymphovascular invasion, and perineural invasion,
which suggests that DUSP4 down-regulation is associated
with gastric cancer progression. Similar to the KM plotter
analysis results, Kaplan-Meier survival analyses revealed that
low DUSP4 expression was significantly associated with
overall survival and recurrence-free survival.
in vivo 35: 131-140 (2021)
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Table IV. Univariate and multivariate Cox regression analyses for overall survival and recurrence-free survival (n=508).
Overall survival
Univariate analysis Multivariate analysis
Variables HR 95% CI p-Value HR 95% CI p-Value
DUSP4 expression 1.395 1.035-1.878 0.028 1.111 0.811-1.523 0.512
(high vs. low)
Age group 1.827 1.357-2.460 <0.001 1.954 1.446-2.641 <0.001
(<65 vs. ≥65)
Tumor size 2.308 1.701-3.130 <0.001 1.080 0.744-1.568 0.686
(<4.0 cm vs. ≥4.0 cm)
Histologic type 1.314 0.962-1.794 0.086
Lauren classification 1.465 1.074-1.999 0.016 1.001 0.714-1.403 0.996
pT category 3.581 2.635-4.866 <0.001
(T1-2 vs. T3-4)
Nodal status 3.361 2.467-4.579 <0.001
(negative vs. positive)
Stage (I vs. II, III) 3.671 2.663-5.059 <0.001 2.635 1.530-4.539 <0.001
LVI (absent vs. present) 2.786 2.023-3.838 <0.001 1.007 0.617-1.642 0.978
PNI (absent vs. present) 3.211 2.370-4.348 <0.001 1.616 1.021-2.557 0.041
Recurrence-free survival
Univariate analysis Multivariate analysis
Variables HR 95% CI p-Value HR 95% CI p-Value
DUSP4 expression 1.776 1.202-2.623 0.004 1.076 0.719-1.610 0.721
(high vs. low)
Age group 0.949 0.638-1.412 0.796
(<65 vs. ≥65)
Tumor size 4.777 3.026-7.542 <0.001 1.335 0.803-2.220 0.266
(<4.0 cm vs. ≥4.0 cm)
Histologic type 2.964 1.820-4.828 <0.001
Lauren classification 3.584 2.179-5.895 <0.001 1.620 0.964-2.721 0.068
pT category 10.091 6.065-16.789 <0.001
(T1-2 vs. T3-4)
Nodal status 9.511 5.651-16.007 <0.001
(negative vs. positive)
Stage (I vs. II, III) 13.636 7.294-25.494 <0.001 5.258 2.169-12.744 <0.001
LVI (absent vs. present) 9.461 5.181-17.275 <0.001 1.777 0.789-4.000 0.165
PNI (absent vs. present) 7.322 4.604-11.644 <0.001 1.430 0.789-2.592 0.238
HR, Hazard ratio; 95% CI, 95% confidence interval; Histologic type, differentiated vs. undifferentiated and others; Lauren classification, intestinal
vs. diffuse and mixed; Stage, AJCC 8th edition; LVI, lymphovascular invasion; PNI, perineural invasion. 
DUSPs are a subclass of protein tyrosine phosphatases
that dephosphorylate threonine and tyrosine residues on
MAPKs and consequently act as negative regulators of
MAPK signaling. DUSP4 is included in the first subfamily
together with DUSP1, DUSP2, and DUSP5. It is mainly
located in the nucleus and is known to show substrate
specificity for MAP kinases p38, c-Jun N-terminal kinase
(JNK), and extracellular-signal-regulated kinase (ERK) (20).
Promoter hypermethylation and copy loss are representative
molecular alterations affecting DUSP4 expression in cancer.
Waha et al. demonstrated de novo methylation and
transcriptional silencing of DUSP4/MKP-2 in primary
glioma tissues and glioma cell lines (21) and Schmid et al.
reported that DUSP4 promoter hypermethylation repressed
DUSP4 expression in diffuse large B-cell lymphoma (9).
Chitale et al. and Mazumdar et al. revealed that copy loss of
DUSP4 at chromosome 8p was found in EGFR-mutant lung
cancers and estrogen receptor (ER)-negative breast cancers
(22, 23). Several studies have shown that the function,
whether a tumor suppressor or tumor promoter, varies
depending on the type of cancer, and the exact impact of
DUSP4 expression on cancer progression and prognosis is
still unclear. 
Recently, Baglia et al. and Gaggianesi et al. reported that
low expression of DUSP4 is generally considered to be
associated with a poor prognosis or aggressive features in
breast cancer (12, 24). Mazumdar et al. demonstrated that
the overexpression of DUSP4 suppressed the MAPK, NF-
ĸB, and Rb signaling pathways and inhibited cell growth
(23). Balko et al. showed that low DUSP4 expression was
correlated with high ERK activity and basal-like subtype.
DUSP4 promoter methylation is most common in basal-like
subtype among the molecular subtypes of breast cancer (25).
Ichimanda et al. reported that colorectal cancer tissue
showed a higher expression of DUSP4 than that in normal
tissue. However, compared to the superficial region, DUSP4
expression decreased in the deep region of the tumor, and the
activity of ERKs increased (26). Saigusa et al. demonstrated
that decreased DUSP4 expression in colorectal cancer was
significantly correlated with tumor progression and distance
metastasis (10). Chitale et al. showed that 8p loss was
observed more frequently in EGFR mutant adenocarcinoma
of the lung, and re-expression of DUSP4 reduced growth and
knockdown of DUSP4 leads to enhanced growth (22). They
suggested that DUSP4 might act as a tumor suppressor in
human malignancy. 
Some authors have reported that DUSP4 in tumor
carcinogenesis may play a role as a tumor promoter. Briston
et al. reported that ERK1/2 activity was increased when
DUSP4 protein was highly expressed and that depletion of
DUSP4 decreased ERK activity in EGFR-mutant lung cancer
cells (5). Lee et al. demonstrated that DUSP4 expression was
increased in thyroid cancer cell lines (TPC1, WRO82-1, and
XTC) (6). Ma et al. showed that high DUSP4 expression was
associated with aggressive features such as lymph node
metastasis and extrathyroidal extension in papillary thyroid
carcinoma (7). Kim et al. reported that high DUSP4
expression was associated with poor prognosis in early T-
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Figure 3. Kaplan-Meier survival analyses. (a) Overall survival was significantly shorter in cases with low expression than in cases with high
expression (Log-rank test, p=0.027). (b) Recurrence-free survival (RFS) was significantly shorter in cases with low expression than in cases with
high expression (Log-rank test, p=0.003).
stage breast cancer (13). Gröschl et al. showed that DUSP4
is associated with microsatellite instability (MSI) in
colorectal cancer and DUSP4 overexpression increased cell
proliferation in colorectal cancer cell lines (27). They
suggested that DUSP4 might act as a tumor promoter in
human malignancy.
In gastric cancer, there is no conclusive report regarding
the exact role of DUSP4 expression in tumor progression and
prognosis. Kang et al. reported that DUSP4 overexpression
increased doxorubicin resistance in gastric cancer cells and
the knockdown of DUSP4 increased the cytotoxicity of
gastric cancer cells to doxorubicin. Up-regulation of DUSP4
promotes the epithelial-mesenchymal transition (14). Xu et
al. revealed that the knockdown of DUSP4 reduced the
mobility and invasiveness of gastric cancer cells, and DUSP4
mRNA expression was increased in gastric carcinoma
compared to that in the adjacent tissues. DUSP4 expression
showed a significant increase in 30 gastric cancer tissues
detected by immunohistochemistry and western blotting (15).
Zhang et al. demonstrated that low DUSP4 expression was
significantly associated with various factors related to cancer
progression, such as larger tumor size, deep invasion of the
tumor, and distant metastasis in a study of 89 patients with
gastric cancer (16). In our study, low DUSP4 expression was
significantly correlated with aggressive phenotypes and poor
prognosis in a large series of 508 patients with gastric cancer.
The association between DUSP4 expression and specific
molecular subtypes was investigated, however, there was no
significant correlation between DUSP4 expression and
specific molecular subtypes. 
As a strength of this study, it was possible to evaluate the
clinicopathological significance of DUSP4 expression in
gastric cancer through larger number of cases than previous
studies, and similar results were confirmed using
bioinformatics analysis. Also, this is the first study to
investigate the association between the expression of DUSP4
and a specific molecular subtype of gastric cancer. However,
there is a limitation in that we only evaluated the expression
of DUSP4 through immunohistochemistry. The molecular
mechanism underlying the role of DUSP4 expression in
gastric cancer was not studied, and further studies such as
DUSP4 promoter hypermethylation are needed.
in vivo 35: 131-140 (2021)
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Figure 4. Analysis using the Kaplan-Meier (KM) plotter demonstrated that low mRNA expression of DUSP4 was associated with unfavorable survival
outcome (n=875; Log-rank test, p<0.001).
In conclusion, our results showed that DUSP4 expression
in gastric cancer and lymph node metastasis was reduced
compared to that in normal tissue and tubular adenoma. Low
DUSP4 expression is associated with cancer progression and
poor prognosis in patients with gastric cancer. Our results
suggest that DUSP4 may act as a tumor suppressor in gastric
cancer. The exact role of DUSP4 in gastric cancer and its
potential as a novel therapeutic target for gastric cancer
should be investigated in further studies.
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